Product information and disease description / Product description / Product informationIndication4 evidence topics · 8 sourcesProposed indication in the NDA“for the treatment of adults with desmoid tumors” (opens the source at this quote in a new tab)CopyFlag“In April 2026, Immunome submitted an NDA to the U.S. FDA for varegacestat for the treatment of adults with desmoid tumors.” (opens the source at this quote in a new tab)CopyFlagProposed indication in the MAA“In October 2026, the EMA validated Immunome’s MAA for varegacestat for the treatment of adults with desmoid tumors.” (opens the source at this quote in a new tab)CopyFlag“If approved, varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors in the European Union (EU)” (opens the source at this quote in a new tab)CopyFlagPopulation of the RINGSIDE phase 3 trial: adults with progressing desmoid tumors“RINGSIDE Phase 3 was a double-blind, placebo (PBO)-controlled study in adults with progressing DT per RECIST v1.1 (NCT04871282).” (opens the source at this quote in a new tab)CopyFlag“Adults with histologically confirmed DT that has progressed in the past 12 months per RECIST 1.1” (opens the source at this quote in a new tab)CopyFlag“Treatment-naïve and previously treated patients” (opens the source at this quote in a new tab)CopyFlag“Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.” (opens the source at this quote in a new tab)CopyFlagRegistry eligibility for RINGSIDE Part B: age 12 years and older“≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.” (opens the source at this quote in a new tab)CopyFlag“Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.” (opens the source at this quote in a new tab)CopyFlag